GOSS: Gossamer Bio, Inc. Stock

by  •  • Comments Off on GOSS: Gossamer Bio, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 174.48
Enterprise Value ($M) 351.39
Book Value ($M) 62.77
Book Value / Share 0.28
Price / Book 2.78
NCAV ($M) 57.37
NCAV / Share 0.25
Price / NCAV 3.04

Profitability (mra)
Return on Invested Capital (ROIC) -0.65
Return on Assets (ROA) -0.82
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 5.94
Current Ratio 5.94

Balance Sheet (mrq) ($M)
Current Assets 306.52
Assets 311.92
Liabilities 249.15
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -173.76
Net Income -179.82
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -159.16
Cash from Investing -110.97
Cash from Financing 190.15

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Hillhouse Capital Management, Ltd. 2.20
02-13 13G/A Vanguard Group Inc 5.16 46.18
02-09 13G Fmr Llc 5.44
02-09 13G/A ARCH Venture Fund IX, L.P.
01-11 13G/A Millennium Management Llc 1.90 -12.07
01-11 13G Artal International S.C.A. 5.80
07-28 13D Growth Equity Opportunities 18 VGE, LLC 8.20
05-10 13G/A State Street Corp 1.39 -95.26
2023-05-05 13G/A BlackRock Inc. 4.90 -14.03

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-05 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI
2023-11-09 10-Q – UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2023-08-08 10-Q – UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2023-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-03 678,762 3,372,772 20.12
2024-05-02 204,987 988,693 20.73
2024-05-01 272,299 135,915 200.35
2024-04-30 189,135 319,485 59.20
2024-04-29 315,643 180,022 175.34

(click for more detail)

Similar Companies
GERN – Geron Corporation GILD – Gilead Sciences, Inc.
GLUE – Monte Rosa Therapeutics, Inc. GRTS – Gritstone bio, Inc.
GTHX – G1 Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io